During the recent session, Vigil Neuroscience Inc (NASDAQ:VIGL)’s traded shares were 20.2 million, with the beta value of the company hitting 1.82. At the last check today, the stock’s price was $2.22, reflecting an intraday gain of 9.36% or $0.19. The 52-week high for the VIGL share is $6.06, that puts it down -172.97 from that peak though still a striking 32.88% gain since the share price plummeted to a 52-week low of $1.49. The company’s market capitalization is $90.76M, and the average intraday trading volume over the past 10 days was 0.23 million shares, and the average trade volume was 230.18K shares over the past three months.
Vigil Neuroscience Inc (VIGL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.44. VIGL has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.47.
Vigil Neuroscience Inc (NASDAQ:VIGL) trade information
Vigil Neuroscience Inc (VIGL) registered a 9.36% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 9.36% in intraday trading to $2.22, hitting a weekly high. The stock’s 5-day price performance is 15.63%, and it has moved by 33.74% in 30 days. Based on these gigs, the overall price performance for the year is -26.97%. The short interest in Vigil Neuroscience Inc (NASDAQ:VIGL) is 0.51 million shares and it means that shorts have 5.31 day(s) to cover.
The consensus price target of analysts on Wall Street is $11, which implies an increase of 79.82% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $11 and $11 respectively. As a result, VIGL is trading at a discount of -395.5% off the target high and -395.5% off the low.
Vigil Neuroscience Inc (VIGL) estimates and forecasts
Statistics show that Vigil Neuroscience Inc has underperformed its competitors in share price, compared to the industry in which it operates. Vigil Neuroscience Inc (VIGL) shares have gone down -44.36% during the last six months, with a year-to-date growth rate less than the industry average at 2.82% against 16.50.
While earnings are projected to return 4.38% in 2025.
VIGL Dividends
Vigil Neuroscience Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Vigil Neuroscience Inc (NASDAQ:VIGL)’s Major holders
Vigil Neuroscience Inc insiders own 21.27% of total outstanding shares while institutional holders control 80.16%, with the float percentage being 101.81%. ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC is the largest shareholder of the company, while 77.0 institutions own stock in it. As of 2024-06-30, the company held over 5.84 million shares (or 14.6419% of all shares), a total value of $23.35 million in shares.
The next largest institutional holding, with 4.21 million shares, is of NORTHPOND VENTURES, LLC’s that is approximately 10.5722% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $16.86 million.
Also, the Mutual Funds coming in first place with the largest holdings of Vigil Neuroscience Inc (VIGL) shares are Vanguard Total Stock Market Index Fund and abrdn Life Sciences Investors. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 710.14 shares. This amounts to just over 1.74 percent of the company’s overall shares, with a $1.62 million market value. The same data shows that the other fund manager holds slightly less at 235.01, or about 0.57% of the stock, which is worth about $0.54 million.
